Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT206 Alone or in Combination With Semaglutide in Obese Participants
NCT07840729Phase 1Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JMT206 in obesity (8 arms), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoint: Incidence of Adverse Events at 19 weeks. Started Oct 2026; status: recruiting.
02
Drugs
JMT206
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07840729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840729.